Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes.... but you made me SEARCH the site FOR it ??? lololol
Fibrobiologics announces direct listing on nasdaq under the stock ticker FBLG
FBLG inaugural Board of Directors...Check out KTRA CEO Robert E. Hoffman
FibroBiologics Announces Direct Listing on NASDAQ ...
PR Newswire
https://www.prnewswire.com › news-releases › fibrobi...
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG. The future of chronic disease cures and cell therapy. (PRNewsfoto/FibroBiologics) ...
$KTRA Whelp folks... Been "wrenching" on the DD for $KTRA Yes there are MANY shares available to borrow and short and THAT in and OF itself is rather criminal...but the ACTUAL # of shares short currently are negligible. The "Days to cover" is between .05 - 1 Day...That nothing...so...not expecting a "squeeze"...
It is now my firm, experienced belief that $KTRA is being manipulated and being "held down" on purpose for reasons of "accumulation" at these "sub .25" levels.
Everyone knows the "nano-float" on this ticker...I believe the sudden climbs yesterday were an "info leak" which caught MM's off guard... The coming news which WILL Rocket $KTRA is either word on their remaining treatment ready for Phase III OR it's word on a "merger / buyout".
Robert E. Hoffman is CEO of $KTRA and on the board of newly NAZ public $FBLG . The "DOTS" are connecting. I believe $KTRA will soon be found!
That is MY DD understanding of the existing float as well 3.38 Mill...
KTRA - very nice volume everyday making us conclude it is getting loaded for a big event better than a pump and dump.
ktra market cap. Les than half a million. Heavily shorted. And 3 months ago was trading at 4 all the ingredients for a mega squeeze in my opinion . No selling for pennies here
Market Cap 530,870 01/05/2024..........................
...yea right, OTCMarkets is a little off on this one.
So, What is the friggin float here?
Through the date hereof (12/18), we have sold an aggregate of 5,537,589 shares of Common Stock
The Prospectus Supplement relates to the offering by the Company of up to $8,700,000 in shares of the common stock of the Company, par value $0.001 (the “Shares”), covered by the Registration Statement. The Shares are being offered and sold by A.G.P./Alliance Global Partners as sales agent (the “Sales Agent”) pursuant to the Sales Agreement between the Company and the Sales Agent dated September 19, 2023 (the “Sales Agreement”).
Number of shares of common stock outstanding as of November 13, 2023 was 3,387,808.
How come??
10q .... Number of shares of common stock outstanding as of November 13, 2023 was 3,387,808.
Todays volume 7,769,209
I think I missed something in my hasty research before I took a position here.
Looks like I’m buying down here. Volume is crazy!!!! This is bound for some type of reversal just based on volume and current price point.
Double 'em up..... This Movement Doesn't make sense last day of the year when no other buyers around.... Figure out how to unwind in 2024.
Spike is Getting Hammered on Volume!!!!! Interesting EOY!!!!! Such a Low Float too!!!
Finding it Hard to Get Bull Support today. May have to Stomach into the CLOSE!!!! Let's see what 100M Shares Traded looks like.
Loaded waiting to see if enough people hanging around yearend for a Squeeze..... I don't post on these setups normally,but this for BISCUITS!!!!
Maybe this Loses today and settles back down, However The Volume in the Pre Market is Crazy and has a good shot at INCENDIARY GAINS!!!!!!!!
IDK!!!!! NOM NOM NOM Looks like feeding to me
Keeps dropping...lol
The First time this AM paid off. Something is up with the Volume. Scanners going off around the world this am. are the warriors up yet?
Thinking about pulling the trigger .27 .28 .29
$.29s again? No Way!!! HAHAHAHAHHAHAHA!!!!!
HOLY BISCUITS and GRAVY!!!! HAHAHAHAHAHA!!!! Living Large while others Stuck in da POOOOOH!!!!
Everyday has another Oyster with a Pearl.....
Gonna Wait for the Warriors to Wake up and join in on SMACKING the Hell out of the $.40s....... Let's see if we can have some fun here....
up 100% pre-market on huge volume. Cant find news?
Just when you think you can’t go lower
On October 31, 2023, the Company announced that preliminary topline results of the GBM AGILE Study showed that VAL-083 did not perform better than the current standards of care in glioblastoma
Doing my DD to see if I want in...very interesting company with a low float. Now, for the background check. ;)
KTRA - Thanks everyone for good information. Todays Buy / Sell Vol 15/33K , not much , but good enaugh for a loss of 7%. Any guess here about timetable ?
https://www.valuewalk.com/is-kintara-therapeutics-a-hidden-gem/
KTRA's next reporting date is February 10, 2023.
1.62 million outstanding unchanged. Show your proof or it didn’t happen.
Wish they would STOP DILUTING this damn stock.
1.62 outstanding unchanged. Proof or it didn’t happen.
Just after the open MM's are trying to shore up the $9.00 range for a road block. How they do this is by
borrowing amounts of stock at the upper PPS range and fill-in where they want to wall.
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1387
|
Created
|
01/25/13
|
Type
|
Free
|
Moderators |
https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.
11/03/21
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |